picotamide

08/01/1998 - "In a controlled, randomized, 6-year trial the safety and efficacy of picotamide, a dual-action antithromboxane agent, were assessed in 50 patients with type 2 diabetes mellitus at increased risk of thrombotic vascular events. "
12/01/1996 - "The kidney weight (g) ( 137 +/- 36; NIDDM: 150 +/- 38; 2p = 0.26), glomerular number (10(3)) (CONTROL: 670 +/- 176; NIDDM: 673 +/- 200; 2p = 0.95), glomerular volume (10(6) micron3) (CONTROL: 6.25 +/- 1.48; NIDDM: 5.71 +/- 1.74; 2p = 0.28) or birth weight (g) ( 3577 +/- 400; NIDDM: 3489 +/- 429; 2p = 0.49) were not different between the groups. "
10/01/2004 - "A total of 1209 adults aged 40-75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. "
05/01/2005 - "Picotamide reduced all-cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease."
01/01/1993 - "Picotamide, a dual TXB synthetase inhibitor and TXB receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM."

10/01/2004 - "The number and the features of aura neurological symptoms were also positively modified by the use of picotamide. "
10/01/2004 - "Picotamide in migraine aura prevention: a pilot study."
05/01/2006 - "Lamotrigine significantly reduced the frequency of MwA attacks, and picotamide together with lamotrigine reduced the duration and/or the occurrence of auras. "
10/01/2004 - "In an open, preliminary trial we evaluated the use of picotamide, an antiplatelet drug, in the prophylactic treatment of migraine aura (MA). "

05/01/1996 - "The safety and efficacy of picotamide long-term treatment in 15 patients with essential thrombocytosis and a positive history of previous thromboembolic events was evaluated. "
05/01/1996 - "This observational long-term trial shows that picotamide treatment in patients with thrombocytosis at high risk of thrombotic events is safe and well tolerated. "
05/01/1996 - "Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study."

01/01/1988 - "Both 150 and 300 mg/kg doses of picotamide significantly (P less than 0.05) improved survival in endotoxin shock at 48 hr. These studies demonstrate that picotamide is a selective thromboxane synthetase inhibitor, and that it may be useful during disease states characterized by increased TxA2 synthesis."

05/01/1999 - "Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial."
05/01/1999 - "We compared the safety and efficacy of two different antiplatelet drugs, aspirin (asa) and picotamide (pico)--a dual antithromboxane agent--in combination with low-intensity oral anticoagulation with warfarin or acenocoumarol in acute myocardial infarction (AMI). "